# Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

> **NCT00440388** · PHASE2 · COMPLETED · sponsor: **Ascenta Therapeutics** · enrollment: 23 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** AT-101
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00440388
- **Lead sponsor:** Ascenta Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2010-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440388, "Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00440388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*